Less frequent Ocrevus infusions are just as effective in controlling MS, but may help limit the risk of side effects, per a ...

During remission, new symptoms typically resolve or improve. MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin, the protective ...

Its pipeline products include PIPE-791, an LPA1 receptor antagonist for idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (PMS); PIPE-307, a selective inhibitor of the M1 receptor ...

This exploratory study assessed the safety and clinical benefit of masitinib in the treatment of primary progressive MS (PPMS) or relapse-free secondary progressive MS (rfSPMS). Methods ...

Cabaletta Bio is getting set to launch a clinical trial testing its cell therapy resecabtagene autoleucel (rese-cel) in people with relapsing and progressive forms of multiple sclerosis (MS).

Good news for preschoolers, parents, guardians and lovers of all things "Ms. Rachel:" She is finally coming to a streaming service near you. Netflix announced the partnership on Tuesday ...

He has written news, reviews, and more as a tech journalist since 2020. Popular YouTube toddler learning show Ms. Rachel is coming to Netflix. It will start with a four-episode season of ...

Now better known as Ms. Rachel, she transformed her living room into a YouTube studio and began creating educational videos. They took off and she is now a YouTube phenomenon that has reached ...

One study also found no significant difference in expanded disability status scale (EDSS) worsening for patients with primary progressive MS and relapsing MS. In terms of qualitative analysis, the ...

Examples include ocrelizumab (Ocrevus ... relapsing-remitting MS active secondary progressive MS An interaction occurs when one substance causes another substance to have a different effect ...

Real-world discontinuation rates of ocrelizumab are low, similar to pivotal trials, with rates between 3.2% and 4.1% for RRMS and PPMS. Side effects are the most common reason for discontinuation ...